search
Back to results

Evaluation of the Evoke Radiofrequency Device for Improvement of Skin Appearance

Primary Purpose

Skin Laxity

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Evoke Radiofrequency Device
Sponsored by
InMode MD Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Skin Laxity

Eligibility Criteria

35 Years - 75 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • - Signed informed consent to participate in the study.
  • Female and male subjects, 35 and 75 years of age at the time of enrolment
  • If female, not pregnant, lactating and must be either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrolment (i.e., oral contraceptives, contraceptive implant, barrier methods with spermicide or abstinence).
  • In addition, negative urine pregnancy test as tested before each treatment and at the last visit for women with childbearing potential (e.g. not menopause).
  • General good health confirmed by medical history and skin examination of the treated area.
  • Willing to have photographs and images taken of the treated areas to be used de-identified in evaluations, publications and presentations.
  • The patients should be willing to comply with the study procedure and schedule, including the follow up visit, and will refrain from using any other aesthetic treatment methods for the last 6 months and during the entire study period.

Exclusion Criteria:

  • - Pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body.
  • Permanent implant in the treated area such as metal plates and screws, silicone implants or an injected chemical substance, unless deep enough in the periostal plane.
  • Current or history of skin cancer, or current condition of any other type of cancer, or premalignant moles.
  • Severe concurrent conditions, such as cardiac disorders, epilepsy, uncontrolled hypertension, and liver or kidney diseases.
  • Pregnancy and nursing.
  • Impaired immune system due to immunosuppressive diseases such as AIDS and HIV, or use of immunosuppressive medications.
  • Patients with history of diseases stimulated by heat, such as recurrent Herpes Simplex in the treatment area, may be treated only following a prophylactic regimen.
  • Poorly controlled endocrine disorders, such as diabetes or thyroid dysfunction.
  • Any active condition in the treatment area, such as sores, psoriasis, eczema, and rash.
  • History of skin disorders, keloids, abnormal wound healing, as well as very dry and fragile skin.
  • History of bleeding coagulopathies or use of anticoagulants in the last 10 days.
  • Any surgery in treated area within 3 months prior to treatment.
  • Six months delay is required if other recent treatments like light, CO2 laser or RF were performed on the same area.
  • Use of Isotretinoin (Accutane®) within 6 months prior to treatment.
  • As per the practitioner's discretion, refrain from treating any condition that might make it unsafe for the patient

Sites / Locations

  • Skincare physicians

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

treatment

Arm Description

Outcomes

Primary Outcome Measures

Evaluate change in skin appearance
Evaluate change in skin appearance comparing pre 6 months post last treatment photographs (as assessed by blinded investigators)
Evaluate Improvement in skin appearance
Evaluate Improvement in skin appearance using 3D Photographic analysis at 6 months follow up visits and compared to the baseline.

Secondary Outcome Measures

Investigator assessment of the skin appearance
Evaluate Investigator assessment of the skin appearance comparing pre and post-treatment using 0 - 4 -points Likert scale at 6 months follow up visits.
Subject assessment of change and satisfaction
Evaluate Subject assessment of change and satisfaction using 0 - 4 -points Likert scale at 6 months follow up visits.
Histological Analysis - Quantitative analysis of collagen fibers (up to 5 subjects)
Quantitative analysis of collagen will be performed with the Image software by semi-automatic segmentation in HSB (Hue-Saturation-Brightness) color system. The change from baseline will be calculated at 3 months time frame.

Full Information

First Posted
December 24, 2020
Last Updated
August 2, 2022
Sponsor
InMode MD Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT04721600
Brief Title
Evaluation of the Evoke Radiofrequency Device for Improvement of Skin Appearance
Official Title
Evaluation of the Evoke Radiofrequency Device for Improvement of Skin Appearance
Study Type
Interventional

2. Study Status

Record Verification Date
May 2022
Overall Recruitment Status
Completed
Study Start Date
November 1, 2020 (Actual)
Primary Completion Date
July 28, 2022 (Actual)
Study Completion Date
July 28, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
InMode MD Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Evaluation of the Evoke Radiofrequency Device for Improvement of Skin Appearance
Detailed Description
The aim of the study is to evaluate the safety, efficacy, patient comfort, and patient satisfaction after Evoke treatment

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Skin Laxity

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
12 (Actual)

8. Arms, Groups, and Interventions

Arm Title
treatment
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
Evoke Radiofrequency Device
Intervention Description
Enrolled subjects will undergo up to 3 successive bi-weekly (every 2 weeks) treatments.Treatment area will include face and under chin
Primary Outcome Measure Information:
Title
Evaluate change in skin appearance
Description
Evaluate change in skin appearance comparing pre 6 months post last treatment photographs (as assessed by blinded investigators)
Time Frame
Day 0, Month 6
Title
Evaluate Improvement in skin appearance
Description
Evaluate Improvement in skin appearance using 3D Photographic analysis at 6 months follow up visits and compared to the baseline.
Time Frame
Day 0, month 6
Secondary Outcome Measure Information:
Title
Investigator assessment of the skin appearance
Description
Evaluate Investigator assessment of the skin appearance comparing pre and post-treatment using 0 - 4 -points Likert scale at 6 months follow up visits.
Time Frame
month 6
Title
Subject assessment of change and satisfaction
Description
Evaluate Subject assessment of change and satisfaction using 0 - 4 -points Likert scale at 6 months follow up visits.
Time Frame
month 6
Title
Histological Analysis - Quantitative analysis of collagen fibers (up to 5 subjects)
Description
Quantitative analysis of collagen will be performed with the Image software by semi-automatic segmentation in HSB (Hue-Saturation-Brightness) color system. The change from baseline will be calculated at 3 months time frame.
Time Frame
Day 0, month 3

10. Eligibility

Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: - Signed informed consent to participate in the study. Female and male subjects, 35 and 75 years of age at the time of enrolment If female, not pregnant, lactating and must be either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrolment (i.e., oral contraceptives, contraceptive implant, barrier methods with spermicide or abstinence). In addition, negative urine pregnancy test as tested before each treatment and at the last visit for women with childbearing potential (e.g. not menopause). General good health confirmed by medical history and skin examination of the treated area. Willing to have photographs and images taken of the treated areas to be used de-identified in evaluations, publications and presentations. The patients should be willing to comply with the study procedure and schedule, including the follow up visit, and will refrain from using any other aesthetic treatment methods for the last 6 months and during the entire study period. Exclusion Criteria: - Pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body. Permanent implant in the treated area such as metal plates and screws, silicone implants or an injected chemical substance, unless deep enough in the periostal plane. Current or history of skin cancer, or current condition of any other type of cancer, or premalignant moles. Severe concurrent conditions, such as cardiac disorders, epilepsy, uncontrolled hypertension, and liver or kidney diseases. Pregnancy and nursing. Impaired immune system due to immunosuppressive diseases such as AIDS and HIV, or use of immunosuppressive medications. Patients with history of diseases stimulated by heat, such as recurrent Herpes Simplex in the treatment area, may be treated only following a prophylactic regimen. Poorly controlled endocrine disorders, such as diabetes or thyroid dysfunction. Any active condition in the treatment area, such as sores, psoriasis, eczema, and rash. History of skin disorders, keloids, abnormal wound healing, as well as very dry and fragile skin. History of bleeding coagulopathies or use of anticoagulants in the last 10 days. Any surgery in treated area within 3 months prior to treatment. Six months delay is required if other recent treatments like light, CO2 laser or RF were performed on the same area. Use of Isotretinoin (Accutane®) within 6 months prior to treatment. As per the practitioner's discretion, refrain from treating any condition that might make it unsafe for the patient
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jeffrey Dover, MD
Organizational Affiliation
Skincare physicians
Official's Role
Principal Investigator
Facility Information:
Facility Name
Skincare physicians
City
Chestnut Hill
State/Province
Massachusetts
ZIP/Postal Code
02467
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Evaluation of the Evoke Radiofrequency Device for Improvement of Skin Appearance

We'll reach out to this number within 24 hrs